First Time Loading...

Reata Pharmaceuticals Inc
NASDAQ:RETA

Watchlist Manager
Reata Pharmaceuticals Inc Logo
Reata Pharmaceuticals Inc
NASDAQ:RETA
Watchlist
Price: 172.36 USD Market Closed
Updated: May 15, 2024

Reata Pharmaceuticals Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Reata Pharmaceuticals Inc
Income from Continuing Operations Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Reata Pharmaceuticals Inc
NASDAQ:RETA
Income from Continuing Operations
-$87.6m
CAGR 3-Years
38%
CAGR 5-Years
-11%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Income from Continuing Operations
$17.1B
CAGR 3-Years
4%
CAGR 5-Years
3%
CAGR 10-Years
1%
Bristol-Myers Squibb Co
NYSE:BMY
Income from Continuing Operations
-$6.1B
CAGR 3-Years
0%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pfizer Inc
NYSE:PFE
Income from Continuing Operations
-$254m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Merck & Co Inc
NYSE:MRK
Income from Continuing Operations
$2.3B
CAGR 3-Years
-22%
CAGR 5-Years
-23%
CAGR 10-Years
-7%
Eli Lilly and Co
NYSE:LLY
Income from Continuing Operations
$6.1B
CAGR 3-Years
0%
CAGR 5-Years
18%
CAGR 10-Years
5%

See Also

What is Reata Pharmaceuticals Inc's Income from Continuing Operations?
Income from Continuing Operations
-87.6m USD

Based on the financial report for Jun 30, 2023, Reata Pharmaceuticals Inc's Income from Continuing Operations amounts to -87.6m USD.

What is Reata Pharmaceuticals Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-11%

Over the last year, the Income from Continuing Operations growth was 71%. The average annual Income from Continuing Operations growth rates for Reata Pharmaceuticals Inc have been 38% over the past three years , -11% over the past five years .